These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


222 related items for PubMed ID: 18817994

  • 1. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R.
    Int J Cardiol; 2010 Feb 04; 138(3):281-9. PubMed ID: 18817994
    [Abstract] [Full Text] [Related]

  • 2. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL, Fitzpatrick JT.
    Ann Pharmacother; 2005 Nov 04; 39(11):1888-96. PubMed ID: 16219899
    [Abstract] [Full Text] [Related]

  • 3. Randomized clinical trials with levosimendan.
    Mebazaa A, Barraud D, Welschbillig S.
    Am J Cardiol; 2005 Sep 19; 96(6A):74G-9G. PubMed ID: 16181826
    [Abstract] [Full Text] [Related]

  • 4. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A.
    J Am Coll Cardiol; 2009 Jun 23; 53(25):2343-8. PubMed ID: 19539144
    [Abstract] [Full Text] [Related]

  • 5. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
    Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A.
    Crit Care Med; 2012 Feb 23; 40(2):634-46. PubMed ID: 21963578
    [Abstract] [Full Text] [Related]

  • 6. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies.
    Landoni G, Mizzi A, Biondi-Zoccai G, Bignami E, Prati P, Ajello V, Marino G, Guarracino F, Zangrillo A.
    Minerva Anestesiol; 2010 Apr 23; 76(4):276-86. PubMed ID: 20332741
    [Abstract] [Full Text] [Related]

  • 7. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G, Fraeman K, Salon J, Chay Woodward T, Sterz R.
    J Med Econ; 2008 Apr 23; 11(3):415-29. PubMed ID: 19450096
    [Abstract] [Full Text] [Related]

  • 8. Is there a place for levosimendan in the intensive care unit?
    Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R.
    Crit Care Resusc; 2007 Sep 23; 9(3):290-2. PubMed ID: 17767458
    [Abstract] [Full Text] [Related]

  • 9. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
    Gong B, Li Z, Yat Wong PC.
    J Cardiothorac Vasc Anesth; 2015 Dec 23; 29(6):1415-25. PubMed ID: 26275522
    [Abstract] [Full Text] [Related]

  • 10. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS, Sandell EP.
    Ital Heart J; 2003 May 23; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [Abstract] [Full Text] [Related]

  • 11. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG, Nikitin N, McGowan J.
    Expert Rev Cardiovasc Ther; 2004 Jan 23; 2(1):9-19. PubMed ID: 15038409
    [Abstract] [Full Text] [Related]

  • 12. Levosimendan compared with dobutamine in low output patients.
    Nieminen MS.
    Minerva Anestesiol; 2003 Apr 23; 69(4):258-63. PubMed ID: 12766717
    [Abstract] [Full Text] [Related]

  • 13. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May 23; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 14. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 15. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
    de Lissovoy G, Fraeman K, Teerlink JR, Mullahy J, Salon J, Sterz R, Durtschi A, Padley RJ.
    Eur J Health Econ; 2010 Apr 01; 11(2):185-93. PubMed ID: 19582491
    [Abstract] [Full Text] [Related]

  • 16. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May 01; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 17. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X, Lei S, Zhu MF, Jiang RL, Huang LQ, Xia GL, Zhi YH.
    J Zhejiang Univ Sci B; 2013 May 01; 14(5):400-15. PubMed ID: 23645177
    [Abstract] [Full Text] [Related]

  • 18. Levosimendan: current status and future prospects.
    Archan S, Toller W.
    Curr Opin Anaesthesiol; 2008 Feb 01; 21(1):78-84. PubMed ID: 18195615
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA, Wagstaff AJ.
    Drugs; 2003 Feb 01; 63(23):2651-71. PubMed ID: 14636085
    [Abstract] [Full Text] [Related]

  • 20. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
    Despas F, Trouillet C, Franchitto N, Labrunee M, Galinier M, Senard JM, Pathak A.
    Acute Card Care; 2010 Mar 01; 12(1):25-30. PubMed ID: 19929264
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.